Clinical trials
Trial starts, readouts, holds and designs.
Stories
-
Hoffmann-La Roche registers Phase III enicepatide trial
The study plans to enroll 8200 participants and is expected to start on January 6, 2027. It aims to evaluate the efficacy and safety of enicepatide, a dual GLP-1/GIP receptor agonist, in reducing major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease.
-
Teva registers Phase 2b and Phase 3 trials of TEV-53408 in non-segmental vitiligo
The study plans to enroll 1020 participants and start November 16, 2026. TEV-53408 will be compared with placebo to see if it helps bring color back to the skin.
-
Incyte posts results of Phase 3 povorcitinib trial in hidradenitis suppurativa
The study enrolled 619 participants and completed its primary phase on January 7, 2025. Results were first posted on ClinicalTrials.gov on November 5, 2026.
-
Gilead posts results of Phase 3 ARTISTRY-2 study of BIC/LEN versus B/F/TAF
Results for the Phase 3 ARTISTRY-2 study were first posted on ClinicalTrials.gov on November 5, 2026. The study enrolled 577 participants and completed primary data collection on October 27, 2025.
-
Acepodia announces first patient dosed in Phase 1 trial of ACE723
The first patient was dosed at a clinical trial site in China on November 5, 2026, marking the first human exposure of ACE723, a GPC3-targeted dual-payload antibody-drug conjugate. ACE723 received IND clearance from the FDA and China's NMPA in September 2026 and TFDA approval in October 2026.
-
AHI changed by -3.88 events per hour on AD109 and 0.21 on placebo in sleep apnea at 6 months
In the Phase 3 LunAIRo trial of 650 analyzed adults with obstructive sleep apnea, the apnea-hypopnea index changed by -3.88 events per hour on AD109 and 0.21 on placebo at 6 months. The record lists full results and safety tables.
-
TAK-279 in two psoriasis types: PASI 75 reached by 37.5 percent with GPP, 80.0 percent with EP at Week 16
In Takeda's open-label Phase 3 study of 18 adults, 37.5 percent with generalized pustular psoriasis and 80.0 percent with erythrodermic psoriasis reached a 75 percent PASI improvement at Week 16. The registry record lists Week 16 results; the Week 52 secondary outcomes are not yet posted.
-
Innovent registers Phase III trial of sintilimab with LCCRT in locally advanced rectal cancer
The study, led by Innovent Biologics (Suzhou) Co. Ltd., plans to enroll 500 participants with locally advanced rectal cancer and is planned to start on November 25, 2026. It evaluates sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy versus the same regimen without sintilimab.
-
Boehringer Ingelheim registers Phase 3 study of verducatib in bronchiectasis
The study, NCT07915219, plans to enroll 1500 participants and begin on January 11, 2027, to evaluate long-term safety and efficacy of verducatib in patients with bronchiectasis. Participants can stay in the study for up to 1 year and 9 months, with primary completion projected for July 31, 2029.
-
Colgate Palmolive registers Phase 3 trial of stannous fluoride vs regular fluoride toothpaste
The study was first posted on ClinicalTrials.gov on November 4, 2026 and currently has 84 participants enrolled. It is planned to complete primary outcomes in April 2027.
-
Ascendis registers Phase 3 trial of navepegritide in hypochondroplasia
The study, led by Ascendis Pharma A/S, plans to enroll 81 children and adolescents with hypochondroplasia and has a planned start date of November 2026. It is a randomized, double-blind, placebo-controlled trial that plans to reach primary completion in October 2028.
-
Novartis posts results of Phase 3 KLU156 trial in uncomplicated P. Falciparum malaria
The study, led by Novartis Pharmaceuticals, enrolled 1720 participants and completed enrollment on March 7, 2024, with primary completion on June 27, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026, confirming the efficacy, safety and tolerability of KLU156 compared with Coartem in adults and children.